The invention relates to a truncated multivalent multimer comprising two or more binding domains, wherein each binding domain binds a different antigen or epitope, and wherein two of said binding domains are paired via a hinge region, wherein the multimer lacks a CH2 or CH3 region. The present invention further comprises two polypeptides that are paired at or near their respective C-terminus comprising two or more disulfide bridges, wherein each of said polypeptide comprise a variable binding domain, comprising a variable region, wherein each variable region binds the same or different antigens or epitopes on an antigen.

The present invention provides a chimeric antigen receptor (CAR), comprising an extracellular part, at least one intracellular signaling domain, and at least one transmembrane domain, wherein the extracellular part of said CAR comprises a) at least one antigen binding domain, and b) at least one cytokine receptor activating or blocking domain. The invention also provides isolated nucleic acid molecule(s) encoding for the said CAR, a cell comprising said nucleic acid molecule(s), a cell expressing said CAR and therapeutic uses of said CAR.

Described are tetravalent, bispecific EGFR/CD16A antigen-binding proteins for engaging NK-cells towards EGFR-positive cells. EGFR/CD16A antigen-binding proteins with different pharmacokinetic (PK) properties are described. Further described is the use of bispecific EGFR/CD16A antigen-binding proteins for the treatment of an EGFR-positive malignancy, such as EGFR-positive tumors.

The present invention relates to the fields of molecular medicine and targeted delivery of therapeutic or diagnostic agents to cells outside the vascular system and into the parenchymal tissue of organs within the body. More specifically, the present invention relates to improved TfR-binding moieties based on shark VNARs capable of crossing the blood brain barrier (BBB) and capable of carrying and releasing cargo specifically targeted to the parenchymal tissue of the brain.

The present invention relates to binding molecules comprising two polypeptide chains, wherein the peptide chains comprise modified EHD2 domains allowing heterodimerization only, thereby preventing homodimers, nucleic acids encoding such binding molecules and uses of such binding molecules or nucleic acids encoding such binding molecules in therapy.

The invention relates to high salt load conditioning during cation exchange chromatography for removal of low isoelectric point product-related impurities during manufacture of recombinant multispecific proteins.

The invention relates to methods for removal of low isoelectric point product-related impurities during cation exchange purification operations.

The present invention relates to methods of treating a B-cell proliferative disorder by administering an anti-CD20/anti-CD3 bispecific antibody, and methods for reduction of adverse effects in response to the administration of the anti-CD20/anti-CD3 bispecific antibody. The present invention further relates to combination treatment methods of treating a B-cell proliferative disorder.

The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the germline cancer antigen MAGE A4. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGE A4 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.

Described herein is a dimeric, bispecific antibody format. Each polypeptide chain of the dimer comprises an immunoglobulin variable region, an immunoglobulin constant region, an Fc polypeptide chain, another immunoglobulin variable region, and another immunoglobulin constant region. Also described are methods of making and using such antibodies.